(Q30992402)

12 October 2017

A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor (English)

1 reference

12 October 2017

Stuart L Emanuel

1

1 reference

12 October 2017

Linda J Engle

2

1 reference

12 October 2017

Ginger Chao

3

1 reference

12 October 2017

Rong-Rong Zhu

4

1 reference

12 October 2017

Carolyn Cao

5

1 reference

12 October 2017

Zheng Lin

6

1 reference

12 October 2017

Aaron P Yamniuk

7

1 reference

12 October 2017

Jennifer Hosbach

8

1 reference

12 October 2017

Jennifer Brown

9

1 reference

12 October 2017

Elizabeth Fitzpatrick

10

1 reference

12 October 2017

Jochem Gokemeijer

11

1 reference

12 October 2017

Paul Morin

12

1 reference

12 October 2017

Brent A Morse

13

1 reference

12 October 2017

Irvith M Carvajal

14

1 reference

12 October 2017

David Fabrizio

15

1 reference

12 October 2017

Martin C Wright

16

1 reference

12 October 2017

Ruchira Das Gupta

17

1 reference

12 October 2017

Michael Gosselin

18

1 reference

12 October 2017

Daniel Cataldo

19

1 reference

12 October 2017

Rolf P Ryseck

20

1 reference

12 October 2017

Michael L Doyle

21

1 reference

12 October 2017

Tai W Wong

22

1 reference

12 October 2017

Raymond T Camphausen

23

1 reference

12 October 2017

Sharon T Cload

24

1 reference

12 October 2017

H Nicholas Marsh

25

1 reference

12 October 2017

Marco M Gottardis

26

1 reference

12 October 2017

Eric S Furfine

27

1 reference

12 October 2017

1 January 2011

1 reference

12 October 2017

Monoclonal Antibodies

1 reference

12 October 2017

3

1 reference

12 October 2017

1

1 reference

12 October 2017

38-48

1 reference

Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2

12 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

FN3: a new protein scaffold reaches the clinic

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Novel agents on the horizon for cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Prediction of immunogenicity for therapeutic proteins: state of the art.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

In-Cell Western analysis of Helicobacter pylori-induced phosphorylation of extracellular-signal related kinase via the transactivation of the epidermal growth factor receptor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

The role of the IGF system in cancer growth and metastasis: overview and recent insights

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Bispecific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Recombinant approaches to IgG-like bispecific antibodies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Recombinant bispecific antibodies for cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycol-modified growth hormone-releasing factor (1-29).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

A revival of bispecific antibodies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Directed evolution of high-affinity antibody mimics using mRNA display

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Bispecific human IgG by design

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

The fibronectin type III domain as a scaffold for novel binding proteins

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Expression and purification of a recombinant metal-binding T4 lysozyme fusion protein.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Epidermal growth factor-related peptides and their receptors in human malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3038010

Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design

21 June 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.3.1.14168

Construction and production of an IgG-like tetravalent bispecific antibody for enhanced therapeutic efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.3.1.14168

Development trends for therapeutic antibody fragments.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.3.1.14168

Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.3.1.14168

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.3.1.14168

Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.3.1.14168

A generalized Wilcoxon test for comparing arbitrarily singly-censored samples

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.3.1.14168

'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21099371

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21099371

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21099371

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/MABS.3.1.14168

1 reference

12 October 2017

1 reference

12 October 2017

PubMed publication ID

21099371

1 reference